Jared Kaltwasser

Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.

Investigators found important differences that may help clinicians better understand how to manage toxicities associated with the therapy.

The findings, which suggest that axicabtagene ciloleucel (axi-cel) may be a good option for a patient group often deemed ineligible for other curative-intent therapy, come from a planned subgroup analysis from the ZUMA-7 trial.

At a median follow-up of 10.7 months, the overall response rate was 63.1%.

The risk of CDI increased at a tertiary hospital, but not at the 2 community hospitals included in the study.

The case report highlights the importance of considering diffuse large B-cell lymphoma (DLBCL) when evaluating patients with persistent periaortic fluid collections.

Randomized controlled trials had lower rates of success, but microbiota restoration still out-performed antibiotics.

Moving to co-administration could also help more adults catch up with vaccination recommendations, the authors said.

Hospitals with the highest work-environment scores were less likely to have above-average Clostridioides difficile infection (CDI) rates.

Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis.

New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.

The scale is meant to better quantify how clusters of symptoms impact patients’ quality of life.

Physicians should proactively ask patients what alternative therapies, if any, they are using.

In some cases, individuals of Puerto Rican descent face lower risk than other Hispanic groups in the United States.

However, Clostridioides difficile (CDI) infection did not appear to affect outcomes, according to the study.

Investigators said longer-term outcomes from chimeric antigen receptor (CAR) T-cell therapies are still a significant question in patients who have non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

Although acne and rosacea treatment are widely covered, treatment for other types of skin conditions are not covered at all, a new report shows.

Patients who have pulmonary arterial hypertension (PAH) often do not feel better after treatment, even if they meet clinical endpoints for improvement.

The majority of respondents living with generalized myasthenia gravis (MG) were not working, the results showed.

Two studies, one of zanubrutinib alone and one that combined the therapy with tislelizumab, showed promising results in a subset of patients.

Investigators said disease-modifying therapies may change the treatment landscape of sickle cell disease (SCD).

A new small case series finds higher rates of symptom flares in individuals who have muscle-specific tyrosine kinase (MuSK)–positive myasthenia gravis (MG) than previous research.

Focus groups show patients who have sickle cell disease (SCD) like the idea of a digital health app for cognitive behavioral therapy (CBT) that allows them to make meaningful connections with people with shared experiences.

Even after adjusting for other risk factors, patients with COPD were more likely to be readmitted to the hospital with heart failure following an acute myocardial infarction, or heart attack.

Health systems participating in the drug discount program did not have fewer disparities than hospitals not participating.

The patient had hemophilia A, but reported no trauma preceding the hematoma.

The training did not, however, affect postoperative limb skeletal muscle weakness or exercise capacity.

Just 29% of patients listed a treatment-response goal among their top personal goals.

No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).

The results of a new focus group offer insights on how and when people with rare diseases are willing to share their personal health information.